ImmuCell Corporation (ICCC) issued a press release on July 9, 2026, reporting a preliminary 11.5% increase in product sales for Q2 2026 compared to Q2 2025, based on unaudited results for the quarter ended June 30, 2026. The press release is filed as Exhibit 99.1 to this 8-K.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding IMMUCELL CORP (ICCC)?

Major stakeholders currently include Vanguard Capital Management LLC ($1.6M), Morgan Stanley ($1.4M), Renaissance Technologies LLC ($960.8K). Based on the latest 13F filings, there are a total of 27 tracked investment funds and institutions maintaining positions in ICCC.

What is the overall institutional sentiment toward ICCC recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $791.8K, driven by 9 managers accumulating shares while 7 reduced their exposure.

Which institutions have been selling or reducing their ICCC positions?

In the latest period, 4 funds trimmed their holdings, and 3 managers completely exited their positions. The aggregate reported sell value was $1.3M.

Are there any notable investors adding ICCC to their portfolios?

Yes, buying activity remains notable. 2 institutions opened new positions in {ticker}, and 7 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.6M.